A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Drug: Placebo
- Registration Number
- NCT04783389
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Brief Summary
This study will evaluate the effect of CBP-201, rademikibart, in adult patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
- Detailed Description
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of CBP-201 on a background of mometasone furoate nasal spray (MFNS) in reducing endoscopic nasal polyp score (NPS) and nasal congestion/obstruction score (NCS) severity in eligible patients with CRSwNP whose disease remains inadequately controlled despite daily treatment with intranasal corticosteroid (INCS) therapy in comparison to placebo. CBP-201 is administered as a subcutaneous (SC) injection. The study is divided into a treatment period of 24 weeks and a follow-up period of 8 weeks.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 40
- Female and male patients aged ≥ 18 and ≤ 75 years at the time of screening.
- Patients who are diagnosed with chronic rhinosinusitis with bilateral polyps despite treatment with systemic corticosteroid within the past 2 years and/or medical contraindication/intolerance to systemic corticosteroids. The polyps have a minimum bilateral nasal polyps score (NPS) of 5 out of a maximum score of 8 with at least a score of 2 for each nostril at screening and baseline evaluated by endoscopy.
- Nasal congestion/blockade/obstruction with moderate or severe symptom severity (Nasal Congestion Score of > 2) at screening and a weekly average severity of > 1 at time of randomization.
- Patients using a documented stable dose of nasal mometasone at least 200 mcg/day, or an equivalent daily dose of another inhaled nasal corticosteroid (INCS), for at least 28 days before randomization and willing to continue the dose for the duration of the study. Note: For patients who are using an alternative INCS product other than mometasone furoate nasal spray (MFNS) prior to the screening visit, the investigator must switch the patient to MFNS at V1.
- Patients willing to enter Patient Diary daily symptom assessments and maintain stable dosing with MFNS with a compliance of at least 70% in the 7 days preceding randomization. Note: Patients must use nasal mometasone at least 200 mcg/day, or equivalent, for at least 28 days before randomization, which can include days prior to screening with supportive documentation. Run-in can be 7-31 days with the compliance determined in the week prior to dosing.
- Male patients who are non-sterilized and sexually active with a female partner of childbearing potential agree to use highly effective contraception from randomization until 8 weeks after last dose.
- Female patients of childbearing potential who are sexually active with a nonsterilized male partner should have a confirmed negative serum beta-human chorionic gonadotropin test at Visit 1 and agrees to use highly effective contraception from signing of informed consent throughout the duration of the study and for 8 weeks after last dose.
- Patient is able to understand and willing to sign the informed consent form (ICF) prior to any study related procedures being performed.
- Willing and able to comply with all study visits and study-related procedures, in the opinion of the Investigator.
A patient who meets any of the following criteria will be ineligible to participate in this study: 10. Patients unable to use MFNS. 11. Patients who are taking or have taken the following prohibited therapies as specified:
1. Systemic steroids within 28 days prior to screening,
2. Other nonbiologic investigational drugs within 60 days (or 5 half-lives, whichever is longer) of screening,
3. Intranasal corticosteroid drops or corticosteroid-administering devices (eg, OptiNose device or stents) within 28 days prior to screening,
4. Non-steroidal immunosuppressants (eg, cyclosporine, methotrexate, azathioprine, mycophenolate, sirolimus, tacrolimus) within 60 days or 5 half-lives, whichever is longer, of screening,
5. Any monoclonal antibody therapy (eg, benralizumab, mepolizumab, omalizumab, reslizumab, dupilumab) or investigational biologic drug for asthma or other diseases within 60 days or 5 half-lives, whichever is longer, of screening,
6. Leukotriene antagonists/modifiers within 7 days prior to screening for patients who were not on continuous treatment for ≥ 30 days prior to screening,
7. Allergen immunotherapy for patients who were not on maintenance treatment for at least 90 days prior to screening
12. Patients who did not respond favorably to previous dupilumab treatment (eg, therapy failure or patient experienced an adverse reaction to treatment). 13. Patients who have undergone any nasal surgery (including polypectomy) within 6 months before screening; or have a history of sinus or nasal surgery modifying the structure of the nose such that assessment of NPS is not possible, or have had uncontrolled epistaxis requiring surgical or procedural intervention, including nasal packing. 14. Patients with conditions/concomitant diseases making them non evaluable at screening or for the primary efficacy endpoint such as: antrochoanal polyps, nasal septal deviation that would occlude at least 1 nostril, acute sinusitis, nasal infection or upper respiratory infection at screening or within 2 weeks before screening, ongoing rhinitis medicamentosa; known or suspected diagnosis of cystic fibrosis; chronic granulomatous disease and granulomatous vasculitis, granulomatosis with polyangiitis (Wegener's Granulomatosis), eosinophilic granulomatous with polyangiitis (Churg-Strauss syndrome), Young's syndrome, primary dyskinetic ciliary syndromes (eg, Kartagener's syndrome) or other dyskinetic ciliary syndromes. 15. Signs or a CT scan suggestive of Allergic Fungal Rhinosinusitis. 16. Patients with co-morbid asthma are excluded if:
1. Forced Expiratory Volume in 1 second (FEV1) ≤ 50% of normal predicted value OR
2. An exacerbation within 90 days prior screening that required hospitalization (\> 24 hours) OR
3. Are on a daily dose of inhaled corticosteroids (ICS) higher than 1000 mcg fluticasone or the equivalent.
17. Known or suspected history of immunosuppression, including history of invasive opportunistic infections, such as aspergillosis, coccidioidomycosis, histoplasmosis, human immunodeficiency virus (HIV), listeriosis, pneumocystosis, or tuberculosis, despite infection resolution; or unusually frequent, recurrent or prolonged infections. Tuberculosis testing would be performed on a country-by-country basis according to local guidelines if required by regulatory authorities or ethics committees. 18. Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb); or hepatitis C (HCV) antibody; or positive HIV serology. Note: Patients who test positive for HBvAb, negative for HBsAg and subsequently confirmed positive for HBsAb, indicating resolved natural infection (confirmed by negative HBV-DNA), may participate. Patients with positive HCV may participate if subsequent viral load is confirmed negative. 19. A helminth parasitic infection diagnosed within 24 weeks prior to the date of informed consent that has not been treated, or has failed to respond to, standard of care therapy. 20. Evidence of infection requiring treatment with systemic antibacterials, antivirals, antifungals, antiparasitics, or antiprotozoals within 7 days before baseline, or viral infections within 14 days before screening that may not have received antiviral treatment. 21. Live, attenuated vaccinations within 28 days prior to screening or planned live, attenuated vaccinations during the study. 22. Pregnant or intent to become pregnant during the study, or breast-feeding women. 23. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and may affect the safety of the patient throughout the study, or influence the findings of the studies or their interpretations, or impede the patient's ability to complete the entire duration of study. 24. Any clinically significant abnormal findings in physical examination, vital signs, safety lab tests during screening/run-in period, which in the opinion of the investigator, may put the patient at risk because of their participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study. 25. Have any of the following laboratory abnormalities at Screening:
1. Eosinophils \>1500 cells/mm3 (or 1.5 x 10E9/L)
2. Platelets \<100000 cells/mm3 (or 100 x 10E9/L)
3. Creatine phosphokinase (CPK) \> 10 upper limit of normal (ULN)
4. Alanine aminotransferase (ALT) \> 2.5 times the ULN
5. Aspartate aminotransferase (AST) ≥ 2.5 times the ULN
6. Bilirubin ≥ 2 times the ULN
26. History of alcohol or drug abuse within 12 months prior to the date informed consent. 27. An allergy to L-histidine, trehalose or Tween (polysorbate) 80 or a history of a systemic hypersensitivity reaction, other than localized injection site reaction, to any biologic drug. 28. Plans to undergo any surgical procedure requiring general anesthesia during the study. 29. History of cancer: Patients who have had basal cell carcinoma, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that the patient is in remission and curative therapy was completed at least 12 months prior to the date informed consent. Note: Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date of informed consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description CBP-201 Dose 1 CBP-201 CBP-201 Dose 1 subcutaneous (SC) injection. CBP-201 Dose 2 CBP-201 CBP-201 Dose 2 subcutaneous (SC) injection. Placebo Placebo Placebo subcutaneous (SC) injection.
- Primary Outcome Measures
Name Time Method Change in Endoscopic Nasal Polyp Score (NPS) From Baseline to Week 24 Change from baseline at Week 24 in endoscopic Nasal Polyp Score (NPS). Endoscopic NPS is assessed by central clinical specialist assessment of video recordings of nasal endoscopy. NPS is graded based on polyp size (recorded as the sum of the right and left nostril scores with a range of 0 to 8; higher scores indicate worse status). The scoring for each nostril is as follows: 0 No polyps, 1 Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate, 2 Polyps reaching below the lower border of the middle turbinate, 3 Large polyps reaching the lower border of the inferior turbinate or large polyps medial to the middle turbinate (i.e., reaching below the middle turbinate), 4 Large polyps causing complete obstruction of the inferior nasal cavity (i.e., touching the floor of the nose). The most improvement improvement possible from baseline would be -8 and the max worsening possible is +8.
Change in Average Daily Nasal Congestion Score (NCS) From Baseline to Week 24 Change from baseline at Week 24 in average daily Nasal Congestion Score (NCS). Daily NCS wase assessed by patient diary from screening and throughout the study by using a 0 to 3 categorical scale for severity of symptoms from none to severe over the past 24 hours. The patient diary prompt: "How would you rate nasal congestion over the last 24 hours?" The answers are: 0 None,1 Minor, 2 Moderate, 3 Severe. The lowest possible weekly average is 0 and the highest possible is 3. The higher the NCS score, the worse the symptoms. Change from baseline in weekly average score is the outcome. Maximal improvement in NCS would be -3 and maximal worsening would be +3.
- Secondary Outcome Measures
Name Time Method Change in Percentage of Maxillary Sinus Volume Occupied by Disease From Baseline to Week 24 CT change from baseline at Week 24 in Lund-Mackay Computed Tomography scores. To calculate the Lund-Mackay score on a CT scan of the paranasal sinuses and ostiomeatal complex, the central blinded reader assigns each sinus a score from 0-2: 0 (no abnormality), 1 (partial opacification) or 2 (complete opacification). The ostiomeatal complex is assigned a score of either 0 (not obstructed) or 2 (obstructed).The sinuses are grouped into: frontal sinus, anterior ethmoidal cells, posterior ethmoidal cells, maxillary sinus, sphenoid sinus, ostiomeatal complex. Each side is graded separately. A combined score from 0 to 24 is possible with 0 being no abnormality and 24 being complete obstruction. The maximal possible change from baseline score would be -24 and the maximal worsening from baseline score would be +24.
Change in University of Pennsylvania Smell Identification Test (UPSIT) From Baseline to Week 24 Change from baseline at Week 24 in University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT is a commercially available, validated, "scratch and sniff" smell test that has 40 items, where each item has 1 correct answer and 3 incorrect answers or "distractors". An UPSIT result is scored out of 40 where a higher score indicates better olfaction (maximum being 40) and 0 indicates the worst possible olfaction outcome. The maximal possible improvement from baseline would be +40 and the worst possible change from baseline would be a score of -40.
Change in Visual Analogue Scale for Rhinosinusitis (VAS-RS) From Baseline to Week 24 Change from baseline at Week 24 in Visual Analogue Scale for Rhinosinusitis (VAS-RS).
The Visual Analogue Scale for Rhinosinusitis (VAS-RS) is a 10 cm linear scale that ranges from "none" to "more than I can imagine" for each of 14 defined nasal symptoms (runny nose, loss of smell, etc). The VAS instructions direct the patient to mark a vertical line at the point that best corresponds to how bothersome their symptoms have been between visits the VAS-RS is collected. Site staff measure the distance from none to the patient's mark for each of the 14 symptoms and adds the total number of cm. The least possible score is 0 reflecting no symptoms and the maximal score is 140 reflecting the worst possible symptoms. The best possible outcome change from baseline to week 24 would be a score of -140 and the worst possible change from baseline score would be +140.Change in Total Nasal Symptom Score (TNSS) From Baseline to Week 24 Change from baseline at Week 24 in Total Nasal Symptom Score (TNSS). The Total Nasal Symptom Score is a Patient Reported Outcome which is a total of 3 sub-question scores which are scored 0-3 (0=no symptoms, 1=mild, 2=moderate, 3=severe) for Nasal Obstruction, Itching/Sneezing, and Secretion/Runny Nose. The total possible TNSS score is 9 representing the worst symptoms and the a score of 0 represents no symptoms. The worst change from baseline to Week 24 would be a score of +9 and the best possible change from baseline score would be -9.
Change in 22-item Sinonasal Outcome Test (SNOT-22) From Baseline to Week 24 Change from baseline at Week 24 in 22-item Sinonasal Outcome Test (SNOT-22) The Sino-Nasal Outcome Test (SNOT-22) is a 22-item list of symptoms and social/emotional consequences related to the patient's rhinosinusitis, using a 5-point scale (0,1,2,3,4,5), where score of 0 indicates No Problem, 2 for Very Mild Problem, 3 for Mild or Slight Problem, 4 for Moderate Problem, and 5 for Problem as bad as it can be. The SNOT-22 score range is 0-110, with higher scores representing worse symptoms associated with disease. A maximum improvement or outcome from baseline would be -110 and a maximum worsening of symptoms from baseline would be +110.
Change in Average Daily Anterior Rhinorrhea Score From Baseline to Week 24 Change from baseline at Week 24 in average daily anterior rhinorrhea score. Participants reported symptoms daily on an electronic diary. The diary prompt was "How would you rate your anterior rhinorrhea (the discharge draining from your nose, "runny nose") in the past 24 hours?" The participant entered a score from 0-4: 0 No noticeable discharge from my nose; 1 Minor discharge from my nose, did not require tissues; 2 Some discharge from my nose, required a few tissues; 3 Significant discharge from my nose; 4 Near constant discharge from my nose. The higher the score the worse the outcome with a range of 0-4. The maximum improvement in weekly average of daily symptoms was -4 and the maximal worsening in symptoms was +4.
Change in Average Daily Posterior Rhinorrhea Score From Baseline to Week 24 Change from baseline at Week 24 in average daily posterior rhinorrhea score. Participants reported symptoms daily on an electronic diary. The diary prompt was "How would you rate your posterior rhinorrhea (postnasal phlegm dripping into your throat) in the past 24 hours?" The participant entered a score from 0-4: 0 No noticeable postnasal drip; 1 Some minor postnasal drip; 2 Moderate postnasal drip; 3 Significant postnasal drip; 4 Near constant postnasal drip.
The higher the score the worse the outcome with a range of 0-4. The maximum improvement in weekly average of daily symptoms was -4 and the maximal worsening in symptoms was +4.Change in Average Daily Loss of Smell Score From Baseline to Week 24 Change from baseline at Week 24 in average daily loss of smell score Participants reported symptoms daily on an electronic diary. The diary prompt was "How would you rate your ability to smell?" The participant entered a score from 0-3: 0 Not able to smell anything; 1 Can smell only strong odors; 2 Can smell some, but not all, odors; 3 Have no problem smelling The maximum improvement in weekly average of daily symptoms was +3 and the maximal worsening in symptoms was -3.
Change in Daily Subject-assessed Nasal Peak Inspiratory Flow (NPIF) From Baseline to Week 24 Change from baseline at Week 24 in daily subject-assessed nasal peak inspiratory flow (NPIF).
Participants performed a nasal peak inspiratory flow (NPIF) maneuver twice daily at home and recorded the result on an electronic diary device. An improvement in flow rate (L/min) is considered an improvement and a decrease in flow rate is considered a worsening of symptoms. A change from baseline improvement in flow rate would be a positive number and a worsening from baseline would be a negative number. MCID is considered to be a change from baseline of approximately 20 L/min.Change From Baseline in Blood Level of IgE From Baseline to Week 32 Change from baseline will be summarized with descriptive statistics in blood level of IgE.
IgE (ng/mL) was measured in blood samples sent to a central clinical laboratory.
A negative change from baseline will be considered a clinical improvement and a positive change from baseline will be considered a lack of improvement.Change From Baseline in Thymus and Activation-regulated Chemokine (TARC) From Baseline to Week 32 Change from baseline will be summarized with descriptive statistics in thymus and activation-regulated chemokine (TARC).
TARC (reported in pg/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. A decrease in TARC will be considered an improvement in clinical outcome and an increase in TARC will be considered a lack of clinical improvement.Change From Baseline in Peripheral Eosinophil Counts From Baseline to Week 32 Change from baseline will be summarized with descriptive statistics in peripheral eosinophil counts.
Eosinophil counts in the blood (reported as 10\^9/L) were determined from blood samples sent to a central clinical laboratory.
A negative change from baseline will be considered a clinical improvement and a positive change from baseline will be considered a lack of clinical improvement.Change From Baseline in Eosinophil Cationic Protein (ECP) From Baseline to Week 32 Change from baseline will be summarized with descriptive statistics in eosinophil cationic protein (ECP).
Eosinophil cationic protein (reported as ng/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. An decrease in ECP will be considered an improvement in outcome and an increase will be considered a lack of improvement in clinical outcome.Change From Baseline in Eotaxin-3 From Baseline to Week 32 Change from baseline will be summarized with descriptive statistics in Eotaxin-3.
Eotaxin-3 (reported in pg/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. A decrease from baseline will be considered a clinically improvement and an increase will be considered a lack of improvement.Change From Baseline in Periostin From Baseline to Week 32 Change from baseline will be summarized with descriptive statistics in periostin.
Periostin (reported in ng/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. A decrease from baseline will be considered a positive clinical outcome and an increase will be be considered to lack a positive outcome.
Trial Locations
- Locations (68)
Connect Investigative Site 104
🇺🇸Dallas, Texas, United States
Connect Investigative Site 123
🇺🇸Cincinnati, Ohio, United States
Connect Investigative Site 120
🇺🇸Houston, Texas, United States
Connect Investigative Site 304
🇨🇳Qingdao, Shandong, China
Connect Investigative Site 305
🇨🇳Xi'an, Shanxi, China
Connect Investigative Site 312
🇨🇳Shanghai, Shanghai, China
Connect Investigative Site 501
🇺🇦Dnipropetrovsk, Dnipro, Ukraine
Connect Investigative Site 508
🇺🇦Ivano-Frankivs'k, Ivano-Frankivs'ka Oblast', Ukraine
Connect Investigative Site 402
🇵🇱Kraków, Malopolskie, Poland
Connect Investigative Site 405
🇵🇱Rzeszow, Podkarpackie, Poland
Connect Investigative Site 408
🇵🇱Warszawa, Mazowieckie, Poland
Connect Investigative Site 401
🇵🇱Bydgoszcz, Kujawsko-Pomorskie, Poland
Connect Investigative Site 507
🇺🇦Ivano-Frankivs'k, Ivano-Frankivs'ka Oblast', Ukraine
Connect Investigative Site 101
🇺🇸Sherman, Texas, United States
Connect Investigative Site 311
🇨🇳Taiyuan, Shanxi, China
Connect Investigative Site 306
🇨🇳Nanjing, Jiangsu, China
Connect Investigative Site 301
🇨🇳Shanghai, Shanghai, China
Connect Investigative Site 111
🇺🇸Chicago, Illinois, United States
Connect Investigative Site 504
🇺🇦Lutsk, Volyns'ka Oblast', Ukraine
Connect Investigative Site 503
🇺🇦Kyiv, Ukraine
Connect Investigative Site 102
🇺🇸Princeton, New Jersey, United States
Connect Investigative Site 114
🇺🇸Miami, Florida, United States
Connect Investigative Site 313
🇨🇳Shenyang, Liaoning, China
Connect Investigative Site 604
🇪🇸Barcelona, Catalunya, Spain
Connect Investigative Site 602
🇪🇸Córdoba, Spain
Connect Investigative Site 122
🇺🇸Tulsa, Oklahoma, United States
Connect Investigative Site 125
🇺🇸La Mesa, California, United States
Connect Investigative Site 409
🇵🇱Lubin, Dolnoslaskie, Poland
Connect Investigative Site 302
🇨🇳Nanning, Guangxi, China
Connect Investigative Site 308
🇨🇳Yangzhou, Jiangsu, China
Connect Investigative Site 106
🇺🇸Austin, Texas, United States
Connect Investigative Site 118
🇺🇸Norfolk, Virginia, United States
Connect Investigative Site 109
🇺🇸Miami, Florida, United States
Connect Investigative Site 406
🇵🇱Zabrze, Slaskie, Poland
Connect Investigative Site 407
🇵🇱Kraków, Malopolskie, Poland
Connect Investigative Site 107
🇺🇸Memphis, Tennessee, United States
Connect Investigative Site 403
🇵🇱Warszawa, Masovian, Poland
Connect Investigative Site 404
🇵🇱Białystok, Podlaskie, Poland
Connect Investigative Site 601
🇪🇸Madrid, Spain
Connect Investigative Site 307
🇨🇳Bengbu, Anhui, China
Connect Investigative Site 303
🇨🇳Chongqing, Chongqing, China
Connect Investigative Site 505
🇺🇦Kyiv, Ukraine
Connect Investigative Site 509
🇺🇦Kharkiv, Kharkivska Oblast, Ukraine
Connect Investigative Site 510
🇺🇦Ivano-Frankivs'k, Ivano-Frankivs'ka Oblast', Ukraine
Connect Investigative Site 502
🇺🇦Kyiv, Ukraine
Connect Investigative Site 506
🇺🇦Poltava, Poltavska Oblast, Ukraine
Connect Investigative Site 112
🇺🇸Tulsa, Oklahoma, United States
Connect Investigative Site 128
🇺🇸Temecula, California, United States
Connect Investigative Site 134
🇺🇸Los Angeles, California, United States
Connect Investigative Site 124
🇺🇸Bakersfield, California, United States
Connect Investigative Site 119
🇺🇸Torrance, California, United States
Connect Investigative Site 126
🇺🇸Chicago, Illinois, United States
Connect Investigative Site 110
🇺🇸White Marsh, Maryland, United States
Connect Investigative Site 105
🇺🇸Rochester, New York, United States
Connect Investigative Site 113
🇺🇸Bronx, New York, United States
Connect Investigative Site 133
🇺🇸Columbus, Ohio, United States
Connect Investigative Site 108
🇺🇸Charleston, South Carolina, United States
Connect Investigative Site 129
🇺🇸Saint George, Utah, United States
Connect Investigative Site 115
🇺🇸Bellingham, Washington, United States
Connect Investigative Site 309
🇨🇳Jingzhou, Hubei, China
Connect Investigative Site 310
🇨🇳Hangzhou, Zhejiang, China
Connect Investigative Site 603
🇪🇸Sevilla, Spain
Connect Investigative Site 127
🇺🇸Saint Louis, Missouri, United States
Connect Investigative Site 130
🇺🇸Birmingham, Alabama, United States
Connect Investigative Site 121
🇺🇸Ann Arbor, Michigan, United States
Connect Investigative Site 116
🇺🇸Tampa, Florida, United States
Connect Investigative Site 132
🇺🇸Louisville, Kentucky, United States
Connect Investigative Site 117
🇺🇸Winston-Salem, North Carolina, United States